References
- Santos FP, Tam CS, Kantarjian H, et al. Splenectomy in patients with myeloproliferative neoplasms: efficacy, complications and impact on survival and transformation. Leuk Lymphoma 2014;55:121–127.
- Lenglet J, Traulle C, Mounier N, et al. Long-term follow-up analysis of 100 patients with splenic marginal zone lymphoma treated with splenectomy as first-line treatment. Leuk Lymphoma 2013 Nov 11. [Epub ahead of print]
- van Leeuwen FE, Klokman WJ, Hagenbeek A, et al. Second cancer risk following Hodgkin's disease: a 20-year follow-up study. J Clin Oncol 1994;12:312–325.
- Dietrich PY, Henry-Amar M, Cosset JM, et al. Second primary cancers in patients continuously disease-free from Hodgkin's disease: a protective role for the spleen?Blood 1994;84:1209–1215.
- Wahner-Roedler DL, Nelson DF, Croghan IT, et al. Risk of breast cancer and breast cancer characteristics in women treated with supradiaphragmatic radiation for Hodgkin lymphoma: Mayo Clinic experience. Mayo Clin Proc 2003;78:708–715.
- Abrahamsen JF, Andersen A, Hannisdal E, et al. Second malignancies after treatment of Hodgkin's disease: the influence of treatment, follow-up time, and age. J Clin Oncol 1993;11:255–261.
- Bhatia S, Robison LL, Oberlin O, et al. Breast cancer and other second neoplasms after childhood Hodgkin's disease. N Engl J Med 1996;334:745–751.
- Gooley TA, Leisenring W, Crowley J, et al. Estimation of failure probabilities in the presence of competing risks:new representations of old estimators. Stat Med 1999;18:695–706.
- Hodgson DC. Late effects in the era of modern therapy for hodgkin lymphoma. Hematology Am Soc Hematol Educ Program 2011:323–329.